65results about "Calcium binding proteins" patented technology

The invention relates to a biomarker combination for clinical benefit of non-small cell lung cancer immunotherapy and application of the biomarker combination. The biomarker for predicting the clinical benefit of the non-small cell lung cancer immunotherapy comprises an immune globulin kappa light chain variable region 1-27 (IGKV1-27), a human leukocyte antigen H (HLA-H), an S100 calcium binding protein A8 (S100A8), a chromogranin A (CHGA), an elastin (ELN) and a nephronectin (NPNT). The biomarkers for predicting the clinical benefit of the immunotherapy of the non-small cell lung cancer can be detected, and the clinical benefit effect of the immunotherapy of the non-small cell lung cancer of a patient is judged by the markers.

Novel nucleic acid sequences, vectors, modified cells, binding agents, peptides and pharmaceutical compositions are provided herein that are useful as a medicament, for example in the prevention or treatment of cancer or viral infections associated with impaired HLA class I antigen presentation. Corresponding methods and uses are also provided herein.

The invention discloses a method for extracting calreticulin from tissues and application. The tissue cell extract extracted by the method contains calreticulin and can be used for preparing drugs or vaccines for preventing cancers. Experimental results show that after the tissue cell extract is immunized for several weeks, specific immune response of an organism can be triggered, cancerous cells in the organism can be removed, and therefore the aim of preventing cancers is achieved. The tissue cell extract provided by the invention can be used as a tumor preventive vaccine for preventing autologous or allogenic tumors and reducing the incidence rate of cancers in healthy people.

The invention discloses a milk-derived polypeptide for promoting osteoblast proliferation and differentiation and application thereof, and belongs to the technical field of bioactive peptides. The invention provides a milk-derived bioactive peptide WLKPDPS. The milk-derived bioactive peptide WLKPDPS has extremely high biological safety and a function of promoting osteoblast proliferation and differentiation. The milk-derived bioactive polypeptide WLKPDPS disclosed by the invention has an obvious effect of promoting osteoblast proliferation, can obviously promote osteoblast mineralization, and is expected to be used for preparing medicines for promoting osteoblast proliferation and preventing osteoporosis. The milk-derived bioactive polypeptide WLKPDPS is convenient to synthesize, can be industrially produced, and has a good application prospect in the fields of foods, medicines, cosmetics and the like.

Provided herein are methods and cell systems for production of a recombinant antibody in cells in which the antibody is directed against a target protein that is natively expressed as an intracellular protein in the cell. Also provided herein are modified cell lines for use in such methods in which the modified cell line is engineered to express a variant target protein that has a mutant epitope of the target epitope of an antibody.

The chimeric signal peptide for protein expression comprises an N region, a hydrophobic region, and a C region, wherein the N region and the C region are from the same signal peptide of a first protein, and the hydrophobic region is from the signal peptide of a second protein, and the first protein is different from the second protein. The first and second proteins can be independently selected from the group consisting of BM40, IL2, HA, insulin, CD33, IFNA2, IgGK leader, AZU, and SEAP.

The present disclosure provides constructs comprising a coding sequence operably linked to a promoter which expresses the polynucleotide in an outer hair cell, wherein the coding sequence encodes a polypeptide (e.g., a heterologous polypeptide). Exemplary constructs include AAV constructs. Also provided are methods of using disclosed constructs for the treatment of hearing loss and / or deafness.

The invention relates to a mutant calreticulin for diagnosis of myeloid malignant tumors. A method for diagnosing myeloid malignancies comprising determining the presence of a mutant allele of a calreticulin gene is disclosed. In addition, genomic sequences, cDNA sequences, mRNA sequences and protein sequences of the mutant calreticulin are also subject matter of the invention. Furthermore, the invention relates to the medical use of inhibitors of the mutant calreticulin.

The present invention relates generally to methods for preventing and / or treating myeloproliferative disorders. More specifically, the myeloproliferative disorders are those associated with the presence of a frameshift mutation in the calreticulin (CALR) gene of a cell involved in the myeloproliferative disorders. The present invention also relates to immunological agents, such as antibodies, to calreticulin, methods for preventing and / or treating myeloproliferative diseases using the immunological agents, and chimeric antigen receptors having extracellular domains based on antibodies to calreticulin.

Novel chimeric peptides comprise an N-cadherin binding domain for binding N-cadherin, which is expressed on the surface of cells, in particular smooth muscle cells, and a fibronectin- binding domain, which binds surrounding extracellular matrix and a binding site for fibronectin. The chimeric peptides can be loaded on to nanoparticles, suitably degradable polar hydrophobic ionic polyurethane (D-PHI) nanoparticles for delivery, which can be incorporated into coatings for medical devices, including stents and balloons.

Provided are a use of recombinant calreticulin in hair growth, hair breeding, hair protection or anti-hair loss and a related product. The recombinant protein is derived from the full length of calreticulin or a fragment thereof, and has the functions of treating hair loss and improving hair by means of injection or application. Therefore, calreticulin is expected to be developed into an effective method and means for treating hair loss and improving hair.

Genetically encoded calcium indicator (GECI) polypeptides and the nucleic acid molecules encoding such polypeptides are provided.

The invention relates to a preparation method of an S100A6 protein with low endotoxin content, and the preparation method comprises the following steps: connecting an S100a6 gene into a pET-28a vector to obtain a pET-28a-S100a6 plasmid; introducing into Escherichia coli, carrying out induced expression, and centrifuging to obtain thalli containing S100A6 protein; cracking, crushing and centrifugally filtering the thalli to obtain a supernatant; performing nickel column purification and Q column chromatography purification on the supernatant to obtain a protein solution 2; and purifying with a desalting column to obtain the S100A6 protein. According to the preparation method, the endotoxin content lt can be obtained; the S100A6 protein can be used for researching the S100A6 protein or gene-related pathways and mechanisms in a living body, so that an effective scheme is provided for the treatment of diseases. The S100A6 protein can be applied to the research of the S100A6 protein or gene-related pathways and mechanisms in the living body. The invention further provides a regulation and control effect of the S100A6 receptor RAGE in CVB3 viral myocarditis, and a new target spot and a new treatment scheme are provided for development of drugs for treating the CVB3 viral myocarditis.

This invention discloses a lactobridged protein-derived calcium chelating peptide and its applications, belonging to the field of bioactive small molecule peptide technology. The calcium chelating peptide provided by this invention is safe and non-toxic, exhibiting better physicochemical activity compared to traditional calcium supplements. Its calcium chelating capacity reaches over 419.36 μg / mg, and it can promote calcium transport in the Caco-2 cell monolayer, thereby improving calcium absorption and bioavailability in the human body, making it suitable for use as a calcium supplement. This invention can develop a new protein source for calcium supplements and makes a significant contribution to the high-value utilization of dairy products.

The invention provides a construction method of a CETN3 knockout cell line, a human brain organ with microhead deformity and application of the human brain organ, and belongs to the field of organoids. The CETN3-deficient stem cells prepared by the method provided by the invention still have normal multiplication capacity and differentiation potential, do not influence the development of organoid, can still develop into organoid with good morphology, but have reduced volume, which is similar to phenotypes appearing in small head malformation patients. The CETN3 knockout embryonic stem cell line is utilized, the cells can be self-organized into a structure similar to the human cerebral cortex through nerve induction and 3D culture, and the phenotype of a small head malformation patient is simulated. By utilizing the organ, the research on the disease mechanism can be promoted, and the medicine can be screened more effectively and conveniently.

The present invention provides novel nucleic acid sequences, vectors, modified cells, binding agents, peptides and pharmaceutical compositions that are useful as agents, for example, in the prevention or treatment of cancer or viral infections associated with impaired HLA class I antigen presentation. The invention further provides a corresponding method and application.

The present disclosure provides constructs that include a coding sequence operably linked to a promoter that expresses a polynucleotide in an outer hair cell, the coding sequence encoding a polypeptide (e.g., a heterologous polypeptide). Exemplary constructs include AAV constructs. Also provided are methods of using the disclosed constructs for the treatment of hearing loss and / or hearing loss.

Provided herein are methods and compositions for treating and / or preventing recurrent Clostridium difficile infection (rCDI), neutropenia, cardiovascular disease (e.g., atherosclerosis and / or stroke), asthma, and / or cancer involving administering to a subject a pharmaceutical composition comprising a purified bacterial mixture.

Novel nucleic acid sequences, vectors, modified cells, binding agents, peptides and pharmaceutical compositions are provided herein that are useful as a medicament, for example in the prevention or treatment of cancer or viral infections associated with impaired HLA class I antigen presentation. Corresponding methods and uses are also provided herein.

This disclosure provides expression systems comprising secretion signals that promote production and / or secretion of proteins of interest, as well as one or more polynucleotides encoding chaperone proteins (e.g., CRT and / or PDIA3) which, as demonstrate herein, enhance production and / or secretion of proteins. Moreover, genetically modified host cells comprising these expression systems are capable of producing high levels of protein of interest, such as bovine lactoferrin (bLF), bovine lactoglobulin (bLG), or ovalbumin (Ova).

The present invention relates to improved protein-based biosensors that are suitable for detection of one or more target molecules in a sample. The biosensors are fully-reversible with dynamic ranges suitable for analytic and diagnostic applications. The biosensors of the present invention may be used in synthetic biology, for example in constructing artificial cellular or extracellular signalling networks.

The invention relates to the technical field of bioengineering, in particular to an S100A4 protein for regulating and controlling immune response as well as a preparation method and application of the S100A4 protein. According to the invention, a HaloTag-S100A4 eukaryotic expression vector is constructed, fusion protein is expressed in cells, resin specificity affinity capture is utilized, protease cleavage release is carried out, and finally the high-purity S100A4 protein is obtained. The S100A4 protein prepared by the invention has excellent biological activity and structural integrity. Due to the adoption of the eukaryotic expression system, the protein can complete correct post-translational modification, the conformation of the protein is highly consistent with that of natural protein, and the protein has high activity without complex renaturation steps. Compared with commercially available prokaryotic expression or naturally extracted S100A4 protein, the protein obtained by the invention has higher purity and fewer impurities, and interference of exogenous components on experimental results is avoided.

The present application provides fusion proteins comprising an interleukin-15 (IL-15) sequence and an interleukin-15 receptor alpha (IL-15R alpha) sequence, the fusion proteins having an endoplasmic reticulum (ER) retention sequence and / or a myristicylation sequence.

This application includes a mammalian mRNA expression construct for producing a protein or polypeptide, the mammalian mRNA expression construct including a modified Munc13-1 molecule.

The present invention provides novel nucleic acid sequences, vectors, modified cells, binding agents, peptides and pharmaceutical compositions for use as agents, for example in the prevention or treatment of cancer or viral infections associated with impaired HLA class I antigen presentation. The invention further provides a corresponding method and application.

The invention discloses a lactobridge protein source calcium chelating peptide and application thereof, and belongs to the technical field of biological small molecule active peptides. The calcium chelating peptide provided by the invention is safe and non-toxic, has better physical and chemical activity compared with a traditional calcium supplement, has the calcium chelating capacity of 419.36 mu g / mg or above, can promote calcium transport in a Caco-2 cell monolayer, can improve absorption and bioavailability of calcium in a human body, and is used as a calcium supplement preparation. According to the invention, a new protein source can be developed for calcium supplements, and an important contribution is made to high-value utilization of dairy products.

The invention provides a thrombocytopenia accompanied with thrombus zebrafish model as well as a construction method and application thereof, belongs to the technical field of biology, and particularly relates to a thrombocytopenia accompanied with thrombus zebrafish model, which is characterized in that CALR del52 is over-expressed in zebrafish somatic cells to obtain transgenic zebrafish; adding an arachidonic acid thrombus inducer into the transgenic zebrafish to induce construction; the nucleotide sequence of the CALR del52 is as shown in SEQ ID NO. 1; the zebrafish model with thrombocytopenia associated with thrombosis disease provided by the invention can be used for screening antithrombotic therapeutic drugs, is short in experimental period and low in dosage, and is beneficial to high-throughput screening of trace antithrombotic active natural products.

Disclosed herein are compositions comprising a peptide containing a CD44 binding site and / or a calcium binding site, as well as methods for stimulating hair growth by using the compositions.

The application relates to a mesenchymal stem cell exosome overexpressing Anxal and a preparation method and application thereof, and belongs to the technical field of inflammatory disease medicine preparation. The umbilical cord mesenchymal stem cell exosome overexpressing Anxal provided by the application is obtained by the following steps: cell electrotransfection of a modified Anxal mRNA sequence which is not easy to degrade into umbilical cord mesenchymal stem cells, culture, collection of cell supernatant, and then super-high-speed centrifugation or tangential flow. The umbilical cord mesenchymal stem cell exosome overexpressing Anxal protein can efficiently improve nerve tissue inflammation caused by trauma, improve nerve function, reduce chronic inflammation of local tissues of limbs caused by diabetes, burns and the like, and accelerate tissue healing.